Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients
Abstract EGFR-TKIs are effective therapies for non–small cell lung cancer (NSCLC) patients with EGFR-activating mutations. However, responses vary within individuals and resistant disease inevitably emerges. A prospective cohort of 130 patients with advanced EGFR mutation NSCLC were enrolled. Pre-an...
Saved in:
Main Authors: | Piyada Sitthideatphaiboon, Pronwasun Simseekeaw, Chinachote Teerapakpinyo, Nicha Zungsontiporn, Wariya Chintanapakdee, Itthi Itthisawatpan, Shanop Shuangshoti, Virote Sriuranpong, Thanisa Tongbai, Chanida Vinayanuwattikun |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-024-83930-2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
by: Kei Sonehara, et al.
Published: (2025-01-01) -
Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report
by: Yukihiro Umeda, et al.
Published: (2025-01-01) -
Emerging targeted therapies in oral oncology: Focus on EGFR inhibition
by: Vishnu Priya Veeraraghavan, et al.
Published: (2024-09-01) -
Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
by: Chen Liao, et al.
Published: (2025-01-01) -
Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
by: Jerry Shu-Hung Kuo, et al.
Published: (2025-01-01)